Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro

Table 7 Effect on the model of gastric cancer by L-OHP, CIK, L-OHP+CIK ( $\bar{x}$ ± S).

Group	n	Abdominal perimeter (cm)	Existed time (d)	Survival rate (35d)
Normal control group	5	8.8 ± 0.4	60 ± 0	5/5
NS control group	5	15.61 ± 0.5	20 ± 3.5	0/5
L-OHP1.125 mg/kg	5	14.45 ± 0.3^a	38 ± 4.2^a	3/5^a
L-OHP2.25 mg/kg	5	12.15 ± 0.2^a	52 ± 3.8^a	4/5^a
CIK2 × 10⁷/0.2 mL	5	13.90 ± 0.2^a	40 ± 4.6^a	3/5^a
CIK4 × 10⁷/0.2 mL	5	11.87 ± 0.2^a	53 ± 4.3^a	4/5^a
L-OHP+CIK	5	8.46 ± 0.3^ab	60 ± 0^ab	5/5^ab

ISSN: 1756-9966